Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC
A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse ...
Read the original at onclive.com ↗
- Topics
- Healthcare
- Tracked via
- “AI Risks”